Search clinical trials for: JAB-3312

Total 2471 results

OHSU Knight Cancer Institute
National Cancer Institute (NCI); Oregon Health and Science University

Terminated

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia

United States
Columbia University

Completed

Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

Breast Cancer | Locally Advanced Malignant Neoplasm

United States
Shaare Zedek Medical Center

Completed

Manipulating the Microbiome in IBD by Antibiotics and FMT (FMT)

Exacerbation of Ulcerative Colitis | Ulcerative Colitis, Active Severe | Crohn's Colitis

Israel, Italy, Canada, Finland, Poland, Spain
GlaxoSmithKline

Completed

Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment

Prostatic Hyperplasia
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)

Small Cell Lung Cancer | Solid Tumor | Non-small Cell Lung Cancer
ImmunityBio, Inc.

Withdrawn

QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Head and Neck Squamous Cell Carcinoma
ImmunityBio, Inc.

Withdrawn

QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

Acute Myeloid Leukemia | High Risk Myelodysplastic Syndrome | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive | Myeloproliferative Neoplasm | Myeloid Sarcoma | Blasts 10 Percent or More of Bone Marrow Nucleated Cells

United States
University of Nebraska
National Cancer Institute (NCI)

Active, not recruiting

Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia

Secondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia

United States
University of Washington
National Cancer Institute (NCI); Bayer

Completed

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | de Novo Myelodysplastic Syndrome | Acute Biphenotypic Leukemia

United States
University of Washington
National Cancer Institute (NCI)

Completed

Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm

Acute Myeloid Leukemia | Acute Leukemia of Ambiguous Lineage | Myeloid Neoplasm

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia

United States
ImmunityBio, Inc.

Withdrawn

QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC

Colorectal Cancer
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | High Risk Myelodysplastic Syndrome

United States
National Cancer Institute (NCI)

Suspended

Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS

Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome | Mixed Phenotype Acute Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | de Novo Myelodysplastic Syndrome | Acute Biphenotypic Leukemia

United States
National Cancer Institute (NCI)

Not yet recruiting

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Acute Myeloid Leukemia
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

Acute Myeloid Leukemia | Previously Treated Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Myelodysplastic Syndrome/Acute Myeloid Leukemia

United States
ImmunityBio, Inc.

Withdrawn

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Urothelial Carcinoma
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

Recurrent Glioblastoma | Diffuse Astrocytoma, IDH-Wildtype

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Gallbladder Cancer AJCC v8 | Stage IIIA Gallbladder Cancer AJCC v8 | Stage IIIB Gallbladder Cancer AJCC v8 | Unresectable Extrahepatic... and other conditions

United States
University of Illinois at Chicago
UCB Pharma

Completed

IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA

Rheumatoid Arthritis

United States
National Human Genome Research Institute (NHGRI)

Terminated

Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome

Pulmonary Fibrosis | Metabolic Disease | Oculocutaneous Albinism | Hermansky-Pudlak Syndrome (HPS) | Platelet Storage Pool Deficiency

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases

Intrahepatic Cholangiocarcinoma | Gallbladder Carcinoma | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Malignant Neoplasm in the Peritoneum | Distal Bile Duct Adenocarcinoma | Stage IV Distal Bile Duct Cancer AJCC v8 | Stage IV Intrahepatic Bile Duct Cancer AJCC v8 | Stage IVB Gallbladder...

United States
National Cancer Institute (NCI)

Active, not recruiting

FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
University of Chicago

Active, not recruiting

Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer (OPTIMA-II)

HNSCC | HPV-Related Squamous Cell Carcinoma

United States
Federico II University

Recruiting

Comparison of Vortioxetine Versus Other Antidepressants With Pregabalin Augmentation in Burning Mouth Syndrome

Burning Mouth Syndrome

Italy
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

Secondary Acute Myeloid Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Acute Myeloid Leukemia Post Cytotoxic Therapy

United States, Canada
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene

Acute Myeloid Leukemia With KMT2A Rearrangement | Acute Myeloid Leukemia With NPM1 Mutation

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Untreated Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts | High Risk Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome | Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 | Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Acute Myeloid... and other conditions

United States
Uma Borate

Suspended

Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
Fred Hutchinson Cancer Center
Pfizer

Completed

Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm

Acute Myeloid Leukemia

United States
GlaxoSmithKline

Completed

Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related Surgery

Thrombosis, Venous
University of Southern California
National Cancer Institute (NCI); Vasgene Therapeutics, Inc

Terminated

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Pancreatic Adenocarcinoma | Head and Neck Squamous Cell Carcinoma | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage... and other conditions

United States
University of California, San Francisco
Amgen

Active, not recruiting

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers

Unresectable Extrahepatic Bile Duct Carcinoma | Unresectable Gallbladder Carcinoma | Stage IIIA Gallbladder Cancer AJCC v7 | Stage IIIB Gallbladder Cancer AJCC v7 | Stage IVA Gallbladder Cancer AJCC v7 | Stage IVB Gallbladder Cancer AJCC v7 | Stage III Intrahepatic Cholangiocarcinoma AJCC v7 | Stage... and other conditions

United States
Benazir Bhutto Hospital, Rawalpindi

Completed

Does Sugared or Sugar Free Chewing Gum Reduces Postoperative Ileus After Laparoscopic Cholecystectomy

Postoperative Ileus.

Pakistan
Jaime Daniel Mondragon
University Medical Center Groningen; Hospital General León; Hospital General...

Recruiting

Dapagliflozin Effect in Cognitive Impairment in Stroke Trial (DECIST)

Metabolic Syndrome | Mild Cognitive Impairment | Dementia, Vascular | Stroke, Ischemic

Mexico
Fred Hutchinson Cancer Center

Recruiting

Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis

Primary Myelofibrosis | Secondary Myelofibrosis

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Takeda; Amgen

Recruiting

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | t(9;22) | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | BCR-ABL1...

United States
National Cancer Institute (NCI)

Completed

Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | High Risk Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Chronic Myelomonocytic Leukemia-2

United States
National Cancer Institute (NCI)

Not yet recruiting

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm | Acute Myeloid Leukemia Post Cytotoxic Therapy
National Cancer Institute (NCI)

Not yet recruiting

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Acute Myeloid Leukemia Post Cytotoxic Therapy | Acute Myeloid Leukemia, Myelodysplasia-Related
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

Mantle Cell Lymphoma | Liver Lymphoma

United States
California State University, Long Beach
National Institute on Drug Abuse (NIDA)

Completed

Behavioral Science Aspects of Rapid Test Acceptance (BSARTA)

Hepatitis B | Hepatitis C | HIV | Syphilis

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Suspended

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Hematopoietic and Lymphoid Cell Neoplasm | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts | Recurrent Acute Lymphoblastic... and other conditions

United States
Emory University
National Cancer Institute (NCI)

Withdrawn

Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial

Stage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Resectable Intrahepatic Cholangiocarcinoma | Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8 | Stage I Intrahepatic Cholangiocarcinoma AJCC v8

United States

Search clinical trials for: JAB-3312

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Romania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations